Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia.
Ther Adv Hematol. 2020;11:2040620720927575
Authors: Karol SE, Pui CH
Although cure rates for pediatric acute lymphoblastic leukemia (ALL) have now risen to more than 90%, subsets of patients with high-risk features continue to experience high rates of treatment failure and relapse. Recent work in minimal residual disease stratification and leukemia genomics have increased the ability to identify and classify these high-risk patients. In this review, we discuss this work to identify and classify patients with high-risk ALL. Novel therapeutics, which may have the potential to improve outcomes for these patients, are also discussed.
PMID: 32537116 [PubMed]